Medicare speeds up coverage reviews for some breakthrough devices

CMS and FDA have announced a new Medicare coverage pathway called RAPID that is intended to speed review for certain breakthrough medical devices. The agencies announced the policy on April 23, 2026, and said it is meant to reduce the lag between FDA authorization and Medicare coverage decisions for eligible devices.

For patients and families, the main takeaway is that this is not a blanket change for all devices. RAPID is aimed at a narrow group of products that meet specific federal criteria.

What RAPID is

RAPID stands for Regulatory Alignment for Predictable and Immediate Device coverage. CMS says the goal is to bring Medicare coverage review and FDA evidence review closer together so manufacturers have earlier clarity about the data Medicare will want and eligible devices may reach beneficiaries sooner after FDA authorization.

In plain language, the agencies want to cut down the delay that can happen after a device clears FDA review but before Medicare decides whether it will cover the device nationally.

Who may qualify

CMS says RAPID is for certain FDA-designated Class II and Class III Breakthrough Devices. FDA’s Breakthrough Devices Program is a voluntary pathway for devices intended to provide more effective treatment or diagnosis for serious or irreversibly debilitating conditions.

CMS also says eligible devices must meet additional study requirements, including an Investigational Device Exemption study involving Medicare beneficiaries and clinical outcomes agreed on by CMS and FDA. For some Class II devices, participation in FDA’s TAP program also matters. That means RAPID is designed for a relatively small slice of devices, not the broader device market.

How this differs from the older timeline

Under the new approach, CMS says it would issue a proposed national coverage determination the same day an eligible device receives FDA market authorization, which would start the required 30-day public comment period. CMS says that could allow Medicare national coverage and payment as soon as two months after market authorization in some cases, compared with roughly a year or more under the older process.

That timing matters because Medicare coverage delays have long been a concern for manufacturers and some patients waiting for access to new technology.

What has not changed

RAPID does not remove evidence requirements. It also does not skip public comment. CMS says the pathway will first be described in a procedural notice, followed by a comment period, and that a final policy would take effect only after a final notice in the Federal Register.

CMS has also said its older Transitional Coverage for Emerging Technologies pathway will be paused for new candidates while the agency focuses on RAPID. CMS’s broader work on electronic prior authorization shows a larger effort to modernize coverage workflows, but that is separate from whether any specific device is covered.

What this could mean for patients

If RAPID works as intended, some Medicare beneficiaries could see faster access to certain new devices once FDA authorizes them. That could matter for people with serious conditions where current options are limited.

But there are still important unknowns. The final procedural notice has not yet been published, and it is not yet clear how often eligible devices will move through RAPID, how much time the process will actually save, or how manufacturers will use it in practice.

What readers can do

If you are asking about a specific device, check whether it is part of FDA’s Breakthrough Devices Program and whether Medicare coverage has actually been determined for your situation. Coverage can vary by device, clinical use, and setting.

If you are a patient considering a device, ask the clinician or hospital whether the device is FDA-authorized, whether Medicare covers it for your condition, and whether any prior authorization or out-of-pocket costs may apply.

If you are a caregiver, it can also help to ask whether there are covered alternatives now while a newer device moves through review.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.